Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Genomic Health (GHDX) Share Price

Media headlines about Genomic Health (NASDAQ:GHDX) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Genomic Health earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.4191200357958 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

Genomic Health (NASDAQ:GHDX) opened at $35.55 on Monday. Genomic Health has a 1 year low of $26.37 and a 1 year high of $35.57.

A number of analysts recently weighed in on the stock. ValuEngine raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday. J P Morgan Chase & Co lowered shares of Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price objective on the stock. in a research report on Wednesday, December 13th. Canaccord Genuity reissued a “buy” rating and issued a $39.00 price objective on shares of Genomic Health in a research report on Wednesday, November 15th. Jefferies Group reissued a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research report on Friday, October 20th. Finally, Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $31.57.

In other news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $29.94, for a total transaction of $149,700.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,379 shares of company stock worth $511,531. Corporate insiders own 46.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Genomic Health (GHDX) Share Price” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-genomic-health-ghdx-share-price.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

What are top analysts saying about Genomic Health? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genomic Health and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit